Filtros de búsqueda

Lista de obras de Filippo Pietrantonio

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer

artículo científico publicado en 2015

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study

artículo científico publicado en 2019

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

artículo científico publicado en 2017

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

artículo científico publicado en 2016

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

artículo científico publicado en 2013

Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.

artículo científico publicado en 2014

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

artículo científico publicado en 2019

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

artículo científico publicado en 2015

BRAF in metastatic colorectal cancer: the future starts now.

artículo científico publicado en 2015

BRAF-mutated metastatic colorectal cancer between past and future.

artículo científico publicado en 2015

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen

artículo científico publicado en 2012

Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study

scientific article published on 08 March 2019

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

artículo científico publicado en 2015

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.

artículo científico

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

artículo científico publicado en 2017

Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients.

artículo científico publicado en 2018

CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer

artículo científico publicado en 2019

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

article

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

artículo científico publicado en 2014

Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer

scientific article published on 25 May 2020

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

artículo científico publicado en 2014

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

artículo científico publicado en 2014

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

artículo científico publicado en 2015

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

artículo científico publicado en 2019

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.

artículo científico publicado en 2019

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.

artículo científico publicado en 2011

Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials

artículo científico publicado en 2015

Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2012

Correction to: Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series.

artículo científico publicado en 2018

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

artículo científico publicado en 2015

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

scientific article published on 06 February 2019

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

artículo científico publicado en 2018

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

artículo científico

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

artículo científico publicado en 2015

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

artículo científico publicado en 2015

Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis

artículo científico

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden

artículo científico publicado en 2020

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

artículo científico publicado en 2016

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

artículo científico publicado en 2017

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram

article

FOLFIRI with cetuximab or bevacizumab: FIRE-3

scientific article published on 24 November 2014

FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

artículo científico publicado en 2014

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

artículo científico publicado en 2015

From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

artículo científico publicado en 2016

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status

artículo científico publicado en 2014

Gastric cancer: Translating novels concepts into clinical practice

scientific article published on 14 August 2019

Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM)

article

Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies

scientific article published on 25 July 2018

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

artículo científico publicado en 2016

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

artículo científico publicado en 2012

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

artículo científico

How the lab is changing our view of colorectal cancer

artículo científico publicado en 2016

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases

artículo científico publicado en 2016

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

artículo científico publicado en 2017

Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study

artículo científico publicado en 2020

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer

artículo científico publicado en 2016

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

artículo científico publicado en 2017

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

artículo científico publicado en 2014

Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies

artículo científico publicado en 2018

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

artículo científico publicado en 2018

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

artículo científico publicado en 2021

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial

scientific article published on 29 September 2020

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

scientific article published on 09 April 2020

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

scientific article published on 04 February 2019

Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

artículo científico publicado en 2013

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

artículo científico publicado en 2012

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

artículo científico publicado en 2019

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

artículo científico publicado en 2013

LightSNiP assay is a good strategy for pharmacogenetics test

artículo científico publicado en 2015

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

artículo científico publicado en 2016

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

artículo científico publicado en 2016

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

scientific article published on 03 July 2019

Management of advanced genitourinary tumors

artículo científico publicado en 2012

Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei

scientific article published on 01 April 2019

MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises.

artículo científico

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

artículo científico publicado en 2017

New perspectives in advanced genitourinary malignancies

artículo científico publicado en 2012

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

artículo científico publicado en 2015

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

artículo científico publicado en 2018

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

artículo científico

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

scientific article published on 24 January 2019

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

article

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases

artículo científico publicado en 2018

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

artículo científico publicado en 2016

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

artículo científico publicado en 2019

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

artículo científico publicado en 2017

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

artículo científico publicado en 2015

Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity

artículo científico publicado en 2014

Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions

artículo científico publicado en 2017

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial

scientific article published on 02 May 2019

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

artículo científico publicado en 2016

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer

artículo científico publicado en 2019

Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

artículo científico publicado en 2017

Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review

artículo científico publicado en 2016

Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.

artículo científico publicado en 2016

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

artículo científico publicado en 2018

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

artículo científico publicado en 2022

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

artículo científico publicado en 2018

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

scientific article published on 01 March 2019

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase

artículo científico publicado en 2018

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

artículo científico publicado en 2018

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

artículo científico publicado en 2012

Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al.

artículo científico publicado en 2015

Role of BAX for outcome prediction in gastrointestinal malignancies.

artículo científico

Role of MGMT as biomarker in colorectal cancer

artículo científico publicado en 2014

Role of cMET in the development and progression of colorectal cancer

artículo científico publicado en 2013

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer

artículo científico publicado en 2011

Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

artículo científico publicado en 2016

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

artículo científico publicado en 2017

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy

scientific article published on 04 September 2013

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

artículo científico publicado en 2015

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis

artículo científico publicado en 2016

TP53 mutations in advanced colorectal cancer: the dark side of the moon.

artículo científico

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

artículo científico publicado en 2017

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer

artículo científico publicado en 2018

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions

artículo científico publicado en 2016

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

artículo científico publicado en 2018

The Landscape of Actionable Gene Fusions in Colorectal Cancer

artículo científico publicado en 2019

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

artículo científico publicado en 2018

The landscape of d16HER2 splice variant expression across HER2-positive cancers

artículo científico publicado en 2019

Toward the molecular dissection of peritoneal pseudomyxoma.

artículo científico publicado en 2016

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

artículo científico publicado en 2021

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

scientific article published on 08 May 2018

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

artículo científico publicado en 2015

Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial

artículo científico publicado en 2020

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

artículo científico publicado en 2016

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

artículo científico publicado en 2017

Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study

artículo científico publicado en 2019

[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]

artículo científico publicado en 2018

miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling.

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda